{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:08Z","timestamp":1788153488012,"version":"build-2803163510"},"reference-count":107,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370137"],"award-info":[{"award-number":["82370137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82370137"],"award-info":[{"award-number":["82370137"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of the Jiangsu Higher Education Institutions","award":["23KJB310021"],"award-info":[{"award-number":["23KJB310021"]}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012515","name":"Cyrus Tang Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012515","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovation and Entrepreneurship, Soochow University","award":["2025C170"],"award-info":[{"award-number":["2025C170"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The catheter is among the most commonly used blood-contacting medical devices, but its use can induce surface-mediated coagulation activation, leading to catheter-related thrombosis (CRT). The occurrence of CRT causes venous thromboembolism and catheter malfunction, but current antithrombotic strategies have unsatisfactory efficacy and safety profiles. Here, we review recent advances in the understanding of the pathology of CRT, particularly the roles of the contact pathway factors, and promising novel therapeutic options. Recent studies using genetically modified animals, factor-deficient plasmas, specific inhibitors and purified systems demonstrated an important contribution of contact pathway factors XII and XI to catheter-related blood clotting. Accordingly, contact pathway inhibition has efficacy comparable to that of heparins in mitigating catheter-related coagulation or intraluminal occlusion in various in vitro and animal models, while having lower bleeding risk. Early human studies suggest potential thromboprotective effects of FXI inhibition in catheter placement and hemodialysis settings. However, inhibition of factors XII or XI may impair the defense against infection or disturb normal cardiac function, respectively. Larger human trials are needed to further confirm the efficacy and safety of these contact pathway inhibitors, and to explore whether low-dose combinations of contact pathway inhibitors with heparins are more effective for CRT protection.<\/jats:p>","DOI":"10.3390\/biom16091256","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1256","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Role of Contact Pathway Factors in Catheter-Related Thrombosis: Emerging Evidence and Therapeutic Strategies"],"prefix":"10.3390","volume":"16","author":[{"given":"Mingyan","family":"Jin","sequence":"first","affiliation":[{"name":"Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunliang","family":"Liu","sequence":"additional","affiliation":[{"name":"Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9203-0456","authenticated-orcid":false,"given":"Song","family":"Lyu","sequence":"additional","affiliation":[{"name":"Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxue","family":"Li","sequence":"additional","affiliation":[{"name":"Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-8191","authenticated-orcid":false,"given":"Jun","family":"Wan","sequence":"additional","affiliation":[{"name":"Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: What causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/jth.15487","article-title":"Venous thromboembolism associated with central venous catheters in patients with cancer: From pathophysiology to thromboprophylaxis, areas for future studies","volume":"19","author":"Debourdeau","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.thromres.2015.08.020","article-title":"Systematic review of anticoagulant treatment of catheter-related thrombosis","volume":"136","author":"Onwuemene","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jamainternmed.2023.8232","article-title":"Complication Rates of Central Venous Catheters: A Systematic Review and Meta-Analysis","volume":"184","author":"Teja","year":"2024","journal-title":"JAMA Intern Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","article-title":"Venous thromboembolism associated with long-term use of central venous catheters in cancer patients","volume":"21","author":"Verso","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(09)60220-8","article-title":"Management of occlusion and thrombosis associated with long-term indwelling central venous catheters","volume":"374","author":"Baskin","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lopez-Rubio, M., Lago-Rodriguez, M.O., Ordieres-Ortega, L., Oblitas, C.M., Moragon-Ledesma, S., Alonso-Beato, R., Alvarez-Sala-Walther, L.A., and Galeano-Valle, F. (2024). A Comprehensive Review of Catheter-Related Thrombosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247818"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.2021013453","article-title":"Prevention of recurrent thrombotic events in children with central venous catheter-associated venous thrombosis","volume":"139","author":"Clark","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e14311","DOI":"10.1111\/eci.14311","article-title":"Catheter-related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs","volume":"55","author":"Girardi","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_11","first-page":"553","article-title":"Critical Review of Clinical Practice Guidelines for Prevention, Diagnosis, and Management of Central Venous Catheter-Related Thrombosis","volume":"126","author":"Rosson","year":"2025","journal-title":"Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-023-00574-4","article-title":"Risk factors for peripherally inserted central catheter-related venous thrombosis in adult patients with cancer","volume":"22","author":"Wang","year":"2024","journal-title":"Thromb. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11239-024-03045-3","article-title":"Construction and validation of a nomogram prediction model for the catheter-related thrombosis risk of central venous access devices in patients with cancer: A prospective machine learning study","volume":"58","author":"Ma","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2050312120929238","DOI":"10.1177\/2050312120929238","article-title":"Risk factors for peripherally inserted central catheter line-related deep venous thrombosis in critically ill intensive care unit patients","volume":"8","author":"Bhargava","year":"2020","journal-title":"SAGE Open Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5492\/wjccm.v12.i3.130","article-title":"Upper extremity deep vein thrombosis: An intensivist\u2019s perspective","volume":"12","author":"Singh","year":"2023","journal-title":"World J. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/bmjspcare-2019-002106","article-title":"Central catheter-associated deep vein thrombosis in cancer: Clinical course, prophylaxis, treatment","volume":"11","author":"Marin","year":"2021","journal-title":"BMJ Support Palliat. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2016.02.011","article-title":"Polyurethane versus silicone catheters for central venous port devices implanted at the forearm","volume":"59","author":"Wildgruber","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"300060518820744","DOI":"10.1177\/0300060518820744","article-title":"Risk factors associated with peripherally inserted central catheter-related venous thrombosis in hospitalized patients of advanced age","volume":"48","author":"Song","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(13)60592-9","article-title":"Risk of venous thromboembolism associated with peripherally inserted central catheters: A systematic review and meta-analysis","volume":"382","author":"Chopra","year":"2013","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bja.2019.01.038","article-title":"Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: An open-label, randomised, two-centre trial","volume":"122","author":"Taxbro","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1538-7836.2010.04126.x","article-title":"Risk factors for catheter-related thrombosis (CRT) in cancer patients: A patient-level data (IPD) meta-analysis of clinical trials and prospective studies","volume":"9","author":"Saber","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_22","first-page":"201","article-title":"The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis","volume":"89","author":"Rosendaal","year":"2004","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11239-015-1175-9","article-title":"A systematic review of patient-related risk factors for catheter-related thrombosis","volume":"40","author":"Leung","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_24","first-page":"393","article-title":"Clinical factors of PICC-RVT in cancer patients: A meta-analysis","volume":"31","author":"Ma","year":"2023","journal-title":"Support Care Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1055\/a-1695-8612","article-title":"Transient Bacteremia Promotes Catheter-Related Central Venous Thrombosis through Neutrophil Extracellular Traps","volume":"122","author":"Chen","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.thromres.2013.08.007","article-title":"Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia","volume":"132","author":"Buccisano","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtha.2022.10.020","article-title":"Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro","volume":"21","author":"Guan","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.athoracsur.2021.05.009","article-title":"Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery","volume":"114","author":"Swartz","year":"2022","journal-title":"Ann. Thorac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12959-016-0111-3","article-title":"DOACs\u2014Advances and limitations in real world","volume":"14","author":"Lee","year":"2016","journal-title":"Thromb. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103242","DOI":"10.1016\/j.arcmed.2025.103242","article-title":"Rivaroxaban Prophylaxis in Peripherally Inserted Central Catheter-Related Thrombosis in Breast Cancer Patients","volume":"56","author":"Sang","year":"2025","journal-title":"Arch. Med. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jth.12527","article-title":"Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: Guidance from the SSC of the ISTH","volume":"12","author":"Zwicker","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jtha.2025.06.028","article-title":"Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation","volume":"23","author":"Yin","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/bloodadvances.2025015842","article-title":"A model of zymogen factor XII: Insights into protease activation","volume":"9","author":"Shamanaev","year":"2025","journal-title":"Blood Adv."},{"key":"ref_36","first-page":"937","article-title":"Factor XII Structure-Function Relationships","volume":"50","author":"Shamanaev","year":"2023","journal-title":"Semin Thromb. Hemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/a-1951-1777","article-title":"Factor XII Explored with AlphaFold\u2014Opportunities for Selective Drug Development","volume":"123","author":"Frunt","year":"2023","journal-title":"Thromb. Haemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.2024025322","article-title":"Structure and interactions of the proteins from the contact system","volume":"146","author":"Emsley","year":"2025","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jtha.2023.02.014","article-title":"A site on factor XII required for productive interactions with polyphosphate","volume":"21","author":"Shamanaev","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/bloodadvances.2021005976","article-title":"Model for surface-dependent factor XII activation: The roles of factor XII heavy chain domains","volume":"6","author":"Shamanaev","year":"2022","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1073\/pnas.76.10.4862","article-title":"Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain","volume":"76","author":"Thompson","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ponczek, M.B. (2021). High Molecular Weight Kininogen: A Review of the Structural Literature. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413370"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/jth.14612","article-title":"Polyphosphate, Zn2+ and high molecular weight kininogen modulate individual reactions of the contact pathway of blood clotting","volume":"17","author":"Wang","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/ATVBAHA.119.313503","article-title":"Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX","volume":"40","author":"Visser","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2014810118","DOI":"10.1073\/pnas.2014810118","article-title":"Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI","volume":"118","author":"Kearney","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2019001643","article-title":"Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways","volume":"135","author":"Noubouossie","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/bloodadvances.2024012613","article-title":"Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood","volume":"8","author":"Wan","year":"2024","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI107799","article-title":"Structural changes accompanying enzymatic activation of human Hageman factor","volume":"54","author":"Revak","year":"1974","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2016-10-744110","article-title":"Proteolytic properties of single-chain factor XII: A mechanism for triggering contact activation","volume":"129","author":"Ivanov","year":"2017","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/S0021-9258(18)53549-3","article-title":"Identification and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI","volume":"268","author":"Baglia","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jth.15149","article-title":"Proteolytic activity of contact factor zymogens","volume":"19","author":"Shamanaev","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1021\/bi00357a017","article-title":"Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats","volume":"25","author":"Chung","year":"1986","journal-title":"Biochemistry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic Pathway of Coagulation and Thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MOH.0000000000000603","article-title":"The rebirth of the contact pathway: A new therapeutic target","volume":"27","author":"Srivastava","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-0031-1276586","article-title":"The plasma contact system 2.0","volume":"37","author":"Maas","year":"2011","journal-title":"Semin Thromb. Hemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/s41467-025-62789-5","article-title":"Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis","volume":"16","author":"Haj","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood.V51.6.1223.1223","article-title":"High Gene Frequency of Factor XI (PTA) Deficiency in Ashkenazi Jews","volume":"51","author":"Seligsohn","year":"1978","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199107183250303","article-title":"Factor XI deficiency in Ashkenazi Jews in Israel","volume":"325","author":"Asakai","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2516.2006.01304.x","article-title":"Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy","volume":"12","author":"Salomon","year":"2006","journal-title":"Haemophilia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: Phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/MBC.0000000000000151","article-title":"A case of a severe factor XI deficiency in patient undergoing hemodialysis without the use of heparin","volume":"25","author":"Takamizawa","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/sdi.13136","article-title":"Successful use of peritoneal dialysis after abdominal surgery in a patient with factor XI deficiency: A case report","volume":"36","author":"Li","year":"2023","journal-title":"Semin. Dial."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jbm.820280309","article-title":"Factor XII fragment and kallikrein generation in plasma during incubation with biomaterials","volume":"28","year":"1994","journal-title":"J. Biomed. Mater. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtha.2022.12.014","article-title":"Titanium is a potent inducer of contact activation: Implications for intravascular devices","volume":"21","author":"Litvak","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: Comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"873975","DOI":"10.3389\/fcvm.2022.873975","article-title":"Plasma Kallikrein Cleaved H-kininogen: An End-Point Marker for Contact Activation in vitro and ex vivo","volume":"9","author":"Palarasah","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1182\/bloodadvances.2022009236","article-title":"Histidine-rich glycoprotein attenuates catheter thrombosis","volume":"7","author":"Malik","year":"2023","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"19378","DOI":"10.1038\/s41598-025-04181-3","article-title":"Contact activation of coagulation in newly inserted indwelling catheters","volume":"15","author":"Naddi","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","article-title":"Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial","volume":"44","author":"Pfeffer","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: Results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: A randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/bloodadvances.2022007586","article-title":"Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation","volume":"7","author":"Tweddell","year":"2023","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102932","DOI":"10.1016\/j.rpth.2025.102932","article-title":"The factor XIa antibody osocimab strongly inhibits clotting in extracorporeal circuits with human blood and in baboons","volume":"9","author":"Samaha","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/rth2.12309","article-title":"Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates","volume":"4","author":"Wallisch","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1038\/s41467-024-51745-4","article-title":"A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1038\/s41467-020-17648-w","article-title":"Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs","volume":"11","author":"Wilbs","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jtha.2024.01.023","article-title":"Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow","volume":"22","author":"Keeling","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"Gailani","year":"1991","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2009-02-203604","article-title":"Factor XI contributes to thrombin generation in the absence of factor XII","volume":"114","author":"Kravtsov","year":"2009","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: An in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"AB194","DOI":"10.1016\/j.jaci.2014.12.1570","article-title":"Development and characterization of an anti-FXIIa monoclonal antibody for the treatment of hereditary angioedema","volume":"135","author":"Cao","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","article-title":"Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation","volume":"142","author":"Cao","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/all.16351","article-title":"Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study","volume":"80","author":"Reshef","year":"2025","journal-title":"Allergy"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00408-023-00615-9","article-title":"Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19","volume":"201","author":"Papi","year":"2023","journal-title":"Lung"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.jtha.2024.06.005","article-title":"Factor XII contact activation can be prevented by targeting 2 unique patches in its epidermal growth factor-like 1 domain with a nanobody","volume":"22","author":"Frunt","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1111\/jth.15870","article-title":"Hereditary angioedema is associated with an increased risk of venous thromboembolism","volume":"20","author":"Grover","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.2023022996","article-title":"Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: A family study","volume":"144","author":"Pirouzifard","year":"2024","journal-title":"Blood"},{"key":"ref_101","first-page":"2390","article-title":"C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis","volume":"141","author":"Grover","year":"2023","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jtha.2025.02.029","article-title":"Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer","volume":"23","author":"Nagy","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e20250049","DOI":"10.1084\/jem.20250049","article-title":"Factor XII-driven coagulation traps bacterial infections","volume":"222","author":"Nickel","year":"2025","journal-title":"J. Exp. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s12325-026-03541-3","article-title":"Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials","volume":"43","author":"Falama","year":"2026","journal-title":"Adv. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1126\/science.abn0910","article-title":"Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure","volume":"377","author":"Cao","year":"2022","journal-title":"Science"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/CIRCULATIONAHA.124.070278","article-title":"Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS","volume":"151","author":"Ji","year":"2025","journal-title":"Circulation"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/ATVBAHA.125.322971","article-title":"Human Genetic Evidence Does Not Support a Causal Role for Reduced FXI Levels in Heart Failure Pathogenesis-Brief Report","volume":"45","author":"Daghlas","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/9\/1256\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:27:20Z","timestamp":1788150440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/9\/1256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["biom16091256"],"URL":"https:\/\/doi.org\/10.3390\/biom16091256","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}